<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03793439</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00017902</org_study_id>
    <nct_id>NCT03793439</nct_id>
  </id_info>
  <brief_title>Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis</brief_title>
  <official_title>Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to determine whether further research is warranted to assess whether
      tofacitinib is an effective steroid sparing treatment for pulmonary sarcoidosis. The primary
      endpoint for this study is a 50% or greater reduction in corticosteroid requirement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives:

      Objective 1: Test the hypothesis that the addition of tofacitinib will allow patients with
      sarcoidosis to have 50% or greater reduction in their corticosteroid requirement without a
      significant decrease in pulmonary function testing, and with a similar quality of life as
      measured by a validated questionnaire (1).

      Objective 2: Test the hypothesis that the addition of tofacitinib will result in
      significantly decreased expression of signal transducer and activator of transcription
      (STAT)-1 dependent gene expression.

      Outline:

      This is a 16-week open-label, interventional, proof of concept, hypothesis-generating study.
      All subjects will receive Tofacitinib 5mg twice daily for 16 weeks. After four weeks on
      Tofacitinib, the corticosteroid will be tapered per a pre-defined protocol; once a reduction
      of 50% has been achieved, any further taper will be per physician discretion. After 16 weeks,
      subjects who meet the primary end-point will be permitted an optional one year open-label
      extension.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label, interventional, proof of concept, hypothesis-generating study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>50% reduction in corticosteroid requirement in at least 60% of subjects.</measure>
    <time_frame>16 weeks</time_frame>
    <description>50% reduction in corticosteroid requirement in at least 60% subjects (or 3/5 of the subjects) by week 16, without significant decline in their pulmonary function—defined as a &gt;15% decline in forced vital capacity (FVC), forced expiratory volume at 1 second (FEV1), or diffusing capacity of lung for carbon monoxide (DLCO) relative to the baseline value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Significant decreases in of peripheral markers of STAT pathway activity</measure>
    <time_frame>16 weeks</time_frame>
    <description>Significant decreases in of peripheral markers of STAT pathway activity using RNA sequencing and CXCL10 levels, both measured before and after 16 weeks of tofacitinib treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Sarcoidosis, Pulmonary</condition>
  <condition>Sarcoidosis Lung</condition>
  <condition>Sarcoidosis</condition>
  <arm_group>
    <arm_group_label>Open-label treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive tofacitinib 5mg twice daily from week 0 to week 16, and a corticosteroid taper starting at week 16. Participants also undergo spirometry, RNA sequence testing, and laboratory evaluations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open-label extension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After 16 weeks, subjects who meet the primary end-point will be permitted an optional one year open-label extension.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial</intervention_name>
    <description>Tofacitinib 5mg oral table twice daily for 16 weeks</description>
    <arm_group_label>Open-label treatment</arm_group_label>
    <other_name>Xeljanz</other_name>
    <other_name>tofacitinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Spirometry</intervention_name>
    <description>Spirometry testing at baseline, week 4, week 8, week 12, and week 16</description>
    <arm_group_label>Open-label treatment</arm_group_label>
    <other_name>Pulmonary function test</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>RNA Sequencing</intervention_name>
    <description>RNA sequencing test at baseline and week 16</description>
    <arm_group_label>Open-label treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Laboratory testing</intervention_name>
    <description>Laboratory testing at baseline and weeks 2, 4, 8, 12 and 16</description>
    <arm_group_label>Open-label extension</arm_group_label>
    <arm_group_label>Open-label treatment</arm_group_label>
    <other_name>Blood work</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroid</intervention_name>
    <description>Taper corticosteroids starting at week 4</description>
    <arm_group_label>Open-label treatment</arm_group_label>
    <other_name>Corticosteroid taper</other_name>
    <other_name>Prednisone taper</other_name>
    <other_name>Steroid taper</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tofacitinib 5mg [Xeljanz] 1 year open-label extension</intervention_name>
    <description>After 16 weeks, subjects who meet the primary end-point will be permitted an optional one year open-label extension.</description>
    <arm_group_label>Open-label extension</arm_group_label>
    <other_name>tofacitinib</other_name>
    <other_name>Xeljanz</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet World Association of Sarcoidosis and other Granulomatous Disorders (WASOG)
             definition of pulmonary sarcoid

          -  Histologically proven sarcoid

          -  Evidence of pulmonary sarcoid on chest radiograph

          -  FVC of &gt; 50%

          -  Require 15-30mg/day of prednisone or equivalent corticosteroid to control sarcoidosis.

          -  Stable dose of prednisone or equivalent corticosteroid for 4 weeks prior to
             enrollment.

        Exclusion Criteria:

          -  May be taking methotrexate but not other immunosuppressive or immunomodulatory
             treatments in the two months prior to study period. This includes but is not limited
             to azathioprine, cyclophosphamide, leflunomide, mycophenolate mofetil, cyclosporine,
             tacrolimus, and biologic medications.

          -  Patients requiring &gt;30mg/day prednisone or equivalent.

          -  Pregnant or lactating women.

          -  Hemoglobin &lt; 9g/dL or hematocrit &lt; 30%

          -  White blood cell count &lt;3.0 K/cu mm

          -  Absolute neutrophil count &lt;1.2 K/cu mm

          -  Platelet count &lt;100 K/cu mm

          -  Subjects with an estimated glomerular filtration rate (GFR) ≤40 ml/min

          -  Subjects with a total bilirubin, aspartate aminotransferase (AST), or alanine
             aminotransferase (ALT) more than 1.5 times the upper limit of normal at screening.

          -  Severe, progressive, or uncontrolled chronic liver disease including fibrosis,
             cirrhosis, or recent or active hepatitis.

          -  History of any lymphoproliferative disorder such as Epstein Barr virus (EBV) related
             lymphoproliferative disorder, history of lymphoma, leukemia, or signs and symptoms
             suggest of current lymphatic disease.

          -  Current malignancy or history of malignancy, with the exception of adequately treated
             or excised non-metastatic basal cell or squamous cell cancer of the skin, or cervical
             carcinoma in situ.

          -  Have or have had an opportunistic infection (e.g., herpes zoster [shingles],
             cytomegalovirus, Pneumocystis carinii, aspergillosis and aspergilloma, histoplasmosis,
             or mycobacteria other than TB) within 6 months prior to screening.

          -  Have a known infection with human immunodeficiency virus (HIV)

          -  Have current signs and symptoms of systemic lupus erythematosus, or severe,
             progressive, or uncontrolled renal, hepatic, hematologic, endocrine, pulmonary,
             cardiac (New York Heart Association class III or IV), neurologic, or cerebral diseases
             (with the exception of sarcoidosis).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jim Rosenbaum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcia A Friedman, MD</last_name>
    <phone>5034948637</phone>
    <email>friedmam@ohsu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kimberly Ogle</last_name>
    <phone>503-494-5711</phone>
    <email>oglki@ohsu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcia A Friedman, MD</last_name>
      <phone>503-494-8637</phone>
      <email>friedmam@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kim Ogle</last_name>
      <phone>503-494-5711</phone>
      <email>oglki@ohsu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Janelle Stevens, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcia Friedman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jim Rosenbaum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rosenbaum JT, Choi D, Wilson DJ, Grossniklaus HE, Harrington CA, Sibley CH, Dailey RA, Ng JD, Steele EA, Czyz CN, Foster JA, Tse D, Alabiad C, Dubovy S, Parekh P, Harris GJ, Kazim M, Patel P, White V, Dolman P, Korn BS, Kikkawa D, Edward DP, Alkatan H, Al-Hussain H, Yeatts RP, Selva D, Stauffer P, Planck SR. Parallel Gene Expression Changes in Sarcoidosis Involving the Lacrimal Gland, Orbital Tissue, or Blood. JAMA Ophthalmol. 2015 Jul;133(7):770-7. doi: 10.1001/jamaophthalmol.2015.0726.</citation>
    <PMID>25880323</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>January 2, 2019</study_first_submitted>
  <study_first_submitted_qc>January 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2019</study_first_posted>
  <last_update_submitted>August 27, 2019</last_update_submitted>
  <last_update_submitted_qc>August 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Jim Rosenbaum</investigator_full_name>
    <investigator_title>Professor of Ophthalmology, Medicine, and Cell Biology, OHSU</investigator_title>
  </responsible_party>
  <keyword>Sarcoidosis</keyword>
  <keyword>Corticosteroid dependent sarcoidosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoidosis, Pulmonary</mesh_term>
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>De-identified individual participant data for all primary and secondary outcomes will be made available.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

